Hudson Valley Investment Advisors Inc. ADV acquired a new stake in Atrion Co. (NASDAQ:ATRI) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 900 shares of the medical instruments supplier’s stock, valued at approximately $767,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Pennsylvania Trust Co boosted its holdings in Atrion by 441.3% in the 1st quarter. Pennsylvania Trust Co now owns 57,540 shares of the medical instruments supplier’s stock valued at $9,082,000 after purchasing an additional 46,911 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in shares of Atrion by 41.6% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 132,363 shares of the medical instruments supplier’s stock worth $116,305,000 after acquiring an additional 38,912 shares during the period. First Trust Advisors LP increased its position in Atrion by 159.6% during the 1st quarter. First Trust Advisors LP now owns 3,979 shares of the medical instruments supplier’s stock worth $3,496,000 after purchasing an additional 2,446 shares in the last quarter. Virginia Retirement Systems ET AL increased its position in Atrion by 100.0% during the 1st quarter. Virginia Retirement Systems ET AL now owns 2,400 shares of the medical instruments supplier’s stock worth $2,109,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Grisanti Capital Management LLC acquired a new position in Atrion during the 1st quarter worth approximately $949,000. 61.80% of the stock is currently owned by institutional investors and hedge funds.
ATRI opened at $741.00 on Friday. The stock has a market cap of $1.36 billion, a PE ratio of 37.72 and a beta of 0.27. Atrion Co. has a twelve month low of $624.00 and a twelve month high of $948.03. The company has a fifty day moving average of $781.19 and a 200-day moving average of $834.40.
In other Atrion news, Director Ronald Nicholas Spaulding sold 170 shares of the firm’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $903.00, for a total value of $153,510.00. Following the transaction, the director now directly owns 2,158 shares of the company’s stock, valued at $1,948,674. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 22.07% of the stock is currently owned by company insiders.
Several equities analysts have issued reports on ATRI shares. BidaskClub upgraded shares of Atrion from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 3rd. ValuEngine cut shares of Atrion from a “buy” rating to a “hold” rating in a research report on Friday, July 26th.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Story: Equity Income
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.